Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
D 7.78 -0.13% -0.01
OCUL closed down 0.13 percent on Tuesday, April 16, 2024, on 59 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 6
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Spinning Top Other -0.13%
Wide Bands Range Expansion -0.13%
Down 3 Days in a Row Weakness -0.13%
Gapped Down Weakness -0.13%
Oversold Stochastic Weakness -0.13%
Doji - Bullish? Reversal -0.26%
Wide Bands Range Expansion -0.26%
Gapped Down Weakness -0.26%
Oversold Stochastic Weakness -0.26%
180 Bearish Setup Bearish Swing Setup -2.63%

   Recent Intraday Alerts

Alert Time
Gap Up Closed about 1 hour ago
Down 1% about 1 hour ago
Reversed from Up about 1 hour ago
Gapped Up (Full) about 1 hour ago
Rose Above Previous Day's High about 2 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ocular Therapeutix, Inc. Description

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Eye Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Diseases Cataracts Incision Treatment Of Glaucoma Allergic Conjunctivitis Cornea Allergology Cataract Surgery Incisions Ocular Hypertension Post Surgical Ocular Inflammation

Is OCUL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.31
52 Week Low 1.995
Average Volume 2,275,744
200-Day Moving Average 4.90
50-Day Moving Average 8.55
20-Day Moving Average 8.74
10-Day Moving Average 8.13
Average True Range 0.54
RSI (14) 37.50
ADX 23.46
+DI 16.01
-DI 25.53
Chandelier Exit (Long, 3 ATRs) 8.67
Chandelier Exit (Short, 3 ATRs) 9.13
Upper Bollinger Bands 10.18
Lower Bollinger Band 7.29
Percent B (%b) 0.17
BandWidth 33.00
MACD Line -0.27
MACD Signal Line -0.12
MACD Histogram -0.1586
Fundamentals Value
Market Cap 894.6 Million
Num Shares 115 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -7.71
Price-to-Sales 11.86
Price-to-Book 83.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.42
Resistance 3 (R3) 8.40 8.17 8.32
Resistance 2 (R2) 8.17 8.01 8.18 8.28
Resistance 1 (R1) 7.98 7.91 8.08 8.00 8.24
Pivot Point 7.75 7.75 7.80 7.76 7.75
Support 1 (S1) 7.56 7.59 7.66 7.58 7.34
Support 2 (S2) 7.33 7.49 7.34 7.30
Support 3 (S3) 7.14 7.33 7.27
Support 4 (S4) 7.16